Current and future management options for myelodysplastic syndromes
Related Experiment Video
Updated: Jun 11, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Jeffrey Bryan1, Elias Jabbour, Hillary Prescott
1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Abstract:
The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments have contributed significantly to advancements in the treatment of MDS: (i) improvements in classification systems and prognostic models; and (ii) the emergence of US FDA-approved agents such as lenalidomide, azacitidine and decitabine. Prior to these developments, supportive care measures consisting of blood and platelet transfusions, haematopoietic growth factors and antimicrobials remained standard of care for the treatment of MDS. As a result of these developments, clinicians are able to provide patient-tailored therapy for specific MDS subgroups. Clinical trials addressing combination therapies with multiple investigational agents as well as novel combination regimens are ongoing. This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Mitral Stenosis III: Medical Management
Cardiomyopathy V: Interprofessional Care
Differentiation of Common Myeloid Progenitor Cells
Mitral Valve Prolapse II: Assessment and Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy

